Coronavirus (COVID-19) Update
AmerisourceBergen and our global businesses are highly engaged during the ongoing spread of the novel COVID-19 “Coronavirus."
Rare and Orphan Diseases
Support that improves outcomes for the smallest patient populations
Committed to providing individualized patient care and support
Uniquely positioned to provide an exceptional level of partnership and program customization
Enhancing the patient experience
Dedicated program support
We understand that unique therapies for rare conditions require our associates and clinicians to develop deep, specialized expertise to offer exceptional support. Our dedicated program teams are focused exclusively on your individual therapies to ensure the highest level of specialization and patient care.
Increased therapy access
Orphan products often face reimbursement challenges that are difficult for patients and providers to navigate. Our team excels in rapidly establishing in-network patient access and coverage for new therapies through contract amendments, letters of agreement and new limited distribution agreements.
Technology Solutions and Clinical Analytics
Insights that improve program optimization
How specialty pharmacies support 30 million Americans with rare diseases
Only 5 percent of rare diseases have an FDA-approved treatment. To accommodate these patients, the health care system needs to go beyond prescribing and dispensing medication. Holistic, personalized care can help patients make individual adjustments aimed at improving quality of life and realizing the full potential of treatment.